RxDoctor Payments Data

John Scheitler, MD

Internal Medicine · Gastonia, NCNPI 1093786360

Payments from drug & device makers

$15,398in general payments, 2019–2025

Across 895 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Supernus Pharmaceuticals, Inc.$1K
  • Novo Nordisk$1K
  • Pfizer$891
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,378100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)91$1,462
Lilly USA, LLC64$1,211
AstraZeneca71$1,197
Supernus Pharmaceuticals, Inc.39$1,184
Novo Nordisk71$1,026
Pfizer54$891
Amgen53$806
Bayer51$709
GSK30$523
Johnson & Johnson23$455
Takeda Pharmaceuticals U.S.A., Inc.23$377
Merck24$366
Aytu Biopharma, Inc.27$340
Boehringer Ingelheim19$322
Sanofi-aventis U.S. LLC13$317
Tris Pharma Inc16$295
Esperion Therapeutics, Inc.14$257
Biohaven Pharmaceutical Holding Company Ltd.11$208
Ironshore Pharmaceuticals Inc.10$200
Cranial Technologies, Inc9$183
Novartis12$180
Xeris Pharmaceuticals, Inc.10$175
Amarin Pharma, Inc.12$174
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$156
Abbott6$142
Kowa Pharmaceuticals America, Inc.11$141
Nestle Healthcare Nutrition Inc.7$139
Paratek Pharmaceuticals, Inc.9$121
Idorsia Pharmaceuticals US Inc6$119
Sanofi Pasteur Inc.6$119
Otsuka America Pharmaceutical, Inc.5$115
Collegium Pharmaceutical, Inc.6$105
Insulet Corporation3$88
CSL Behring5$74
Phathom Pharmaceuticals, Inc.6$61
Corcept Therapeutics4$59
Biomarin Pharmaceutical Inc.2$51
Neos Therapeutics, LP3$51
Boston Scientific3$51
Dexcom, Inc.2$46
Lundbeck LLC2$44
Jazz Pharmaceuticals Inc.3$43
Eisai Inc.3$42
E.r. Squibb & Sons, L.L.C.3$40
Shire North American Group Inc3$39
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$39
Seqirus USA Inc2$38
Teva Pharmaceuticals USA, Inc.3$37
Antares Pharma, Inc.2$36
Adlon Therapeutics L.p.2$36
Genentech USA, Inc.2$33
Vivus LLC2$32
Nevro Corp.2$30
Scilex Pharmaceuticals Inc.2$27
Vanda Pharmaceuticals Inc.1$25
Neurocrine Biosciences, Inc.1$22
Masimo Corporation1$21
Exact Sciences1$21
Biohaven Pharmaceuticals, Inc.1$21
Corium, LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,398 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$192,385
Medicare patients
247
Services billed
2,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$121,205
EliquisApixaban87$84,983
JardianceEmpagliflozin58$58,514
RybelsusSemaglutide25$46,865
FarxigaDapagliflozin Propanediol44$44,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$38,262
XareltoRivaroxaban34$34,559
JanuviaSitagliptin Phosphate20$23,860
Bydureon BciseExenatide Microspheres17$21,012
MounjaroTirzepatide19$19,354
LinzessLinaclotide20$15,081
TrulicityDulaglutide13$14,900
ErythromycinErythromycin Base12$7,881
KerendiaFinerenone12$7,689
ShingrixVaricella-Zoster Ge/As01b/Pf28$6,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,026$168,071108 claims
PfizerEliquis, Abrysvo$891$89,145100 claims
Boehringer IngelheimJardiance$322$58,51458 claims
AstraZenecaFarxiga, Symbicort$1,197$48,00857 claims
GSKTrelegy Ellipta, Shingrix$523$44,55275 claims
Johnson & JohnsonXarelto$455$34,55934 claims
Lilly USA, LLCMounjaro, Trulicity$1,211$34,25532 claims
MerckJanuvia$366$23,86020 claims
AbbVieLinzess, Synthroid$1,462$20,01761 claims
BayerKerendia$709$7,68912 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$377$5,77812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →